mRNA, ATG at bp 1 032, is preceded by an alternative initiation code, CTG at bp 513, whose expression predicts a longer PTEN variant, termed PTENLong. PTEN-Long is a 576 amino acid long enzyme with active phosphatase function toward the lipid target Phosphatidylinositol (3,4,5)-triphosphate, PIP3. PTEN-Long is endogenously expressed in human cell lines (reportedly HEK293 and T47D) and normal tissues (breast and brain), and reductions of its expression level have been observed in both human breast tumor samples and a mouse model of glioblastoma. Importantly, the authors revealed that the additional 173 amino acids uniquely found in PTEN-Long encode a secretion signal sequence that allows this enzyme to be secreted into the extracellular environment. Once secreted, PTEN-Long can be absorbed by recipient cells, where it functions as normal PTEN by inhibiting the PI3K pathway and inducing apoptosis. Thus, PTEN-Long acts as tumor suppressor in a cell non-autonomous manner.
In line with these findings, a previous report by Putz et al. [8] had already demonstrated that a secreted canonical PTEN -with an ATG at bp 1 032 -can be part of the intercellular signaling machinery, as the protein was found in exosomes, which are nanovesicles originating from endosomes and released into the extracellular space [9] . Indeed, endogenous and overexpressed PTEN was found to be actively exported outside the cytoplasmic membrane through exosomal trafficking, and later internalized by recipient cells with consequent functional effects (Figure 1, top panel) .
Taken together, these results lead us to reconsider the conventional wisdom about PTEN, also raising a number of new and exciting questions. For instance, the identification of an alternative translation start site on PTEN mRNA points to an unexpectedly complex regulatory post-transcriptional network governing the expression of this major tumor suppressor, which from now on must be regarded as exhibiting both cell autonomous and non-autonomous properties. Yet the molecular mechanisms that favor the expression of conventional PTEN vs PTEN-Long remain to be determined, and no doubt promise important therapeutic implications. To this end, it is important to (1) perform a thorough molecular and biological characterization of PTEN-Long, aiming at a comprehensive analysis of its expression profile across tissues; (2) identify the mechanisms regulating the intercellular recognition of the enzyme between donor and recipient cells; (3) evaluate whether PTEN-Long affects cells in either close proximity (via a paracrine signal) or across long distances (in an endocrine scenario); and (4) understand whether PTEN-Long indeed displays a superior trafficking ability to a canonical PTEN (short isoform). The generation and characterization of conditional Pten Knock-Out or Pten Knock-In mouse mutants will become extremely informative to assess the tissue-specific rate and the consequences of intercellar Pten trafficking.
However, there is more than one side to the story of the complicated relationship between PTEN and PTEN-Long. While wild-type PTEN and PTEN-Long both exert intra-and extra-cellular functions in suppressing tumorigenesis, the high incidence of germline and somatic PTEN mutations -either expressed as secreted PTEN-Long or -Short -can lead to unpredicted tumorigenic effects in a cell non-autonomous manner. Indeed, as sporadic PTEN mutations are commonly found in neoplastic cells [10] , through expression and secretion of mutated PTEN, these mutations could eventually propagate their aberrant signal to the tumor microenvironment and interfere with the tumor-suppressive endogenous activity of wild-type PTEN. Although tissues can be differentially sensitive to loss of PTEN functions, epithelial cells are reportedly extremely susceptible to even partial reduction of PTEN levels [11, 12] , leading to a more pronounced tumor-prone condition, and potentially a higher sensitivity to secreted mutated PTEN (Figure 1, bottom panel) .
Regardless of the physiological processes that regulate expression and secretion of PTEN-Long, the second major discovery that Hopkins et al. have reported is their successful purification of active PTEN-Long, which is obviously of high relevance to the development of novel therapeutic approaches to cancer. Indeed, following the identification of the PTEN-long isoform, the authors went on to explore potential therapeutic applications by performing intraperitoneal (IP) injections of purified PTEN-Long into mice. Here they found that the protein was assimilated by several tissues and, by inhibiting Akt signaling, also induced an increase in blood glucose levels. Importantly, to further test the tumor-suppressive function of PTEN-Long on growing tumors, the authors performed in vivo treatments on a series of established xenograft models using multiple human cancer cell lines (U87MG, MDA-MB-468, HCC70, SUM149, HCT116). Notably, they found that IP injection of purified PTEN-Long led to uptake of the enzyme by tumor cells, which effectively caused tumor regression in most of the cell lines analyzed.
Taken together, these findings are exciting because they may offer a new and straightforward opportunity for cancer prevention and therapy: although research into the therapeutic effects of PTEN-Long is still in its infancy, we may dream of someday prescribing pills made of PTEN. 
